rVIIa-FP (CSL689)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for rVIIa-FP (CSL689), covering 2017-04-26 to 2019-08-28. Get the full timeline:
Most recent: Clinical Trial Update: Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors [Phase 2, Phase 3]